Using MIPs for medicine
– Imprinting a difference – for patients
Welcome to MipSalus
MipSalus is dedicated to developing new, non-systemic pharmaceutical drugs for treatment of metabolic orphan diseases
New proprietary drug
MipSalus is developing a new proprietary drug – the first in a new class of medicines – for the treatment of all variants of HPA (Hyperphenylalaninemia)
The disease
Phenylketonuria (PKU) is a serious, congenital, lifelong metabolic disease caused by a defect in the phenylalanine hydroxylase (PAH) enzyme.
Home sensor
MipSalus is committed to developing a home sensor allowing PKU patients to conveniently monitor the concentration of phenylalanine (Phe) in their blood.
ABOUT THE COMPANY
MipSalus is a biotech company with leading-edge expertise in transforming Molecular Imprinted Polymers (MIPs) into a new class of medicines. MipSalus currently focuses on developing a breakthrough treatment of the rare and potentially invalidating disease Phenylketonuria (PKU) using phenylalanine-binding MIPs to block the uptake of dietary phenylalanine.
The name MipSalus is a combination of the abbreviation MIP – Molecular Imprinted Polymers – and Salus, the ancient Roman goddess of health and prosperity.
Recently, as a spin-off of the PKU drug project and using the Phe-binding MIPs, MipSalus has initiated development of a home sensor allowing PKU patients to monitor their disease and swiftly adjust food and medication.